A Conversation on the Role of Rapid-Acting Therapies in the Management of Major Depressive Disorder

Experts in psychiatry focus on the role of rapid-acting therapies, specifically GABAA receptor modulators in the management of major depressive disorder (MDD). The discussion explores their mechanism of action, their clinical utility as an effective treatment option, and the ongoing research efforts within this area.

EP. 1: Overview of Rapid-Acting Therapies in Major Depressive Disorder (MDD)

September 28th 2023

Carmen Kosicek, MSN, PMHNP-BC, reviews the definition of “rapid-acting” therapies as well as their role in treating major depressive disorder (MDD).

EP. 2: Defining Features of Rapid-Acting Therapies in MDD

September 28th 2023

Roger S. McIntyre, MD, FRCPC, discusses the history of psychiatry and the conventional treatment and response times, leading into the current treatment armamentarium for treatment of major depressive disorder (MDD).

EP. 3: Communicating With Patients About MDD Treatment

October 5th 2023

Roger S. McIntyre, MD, FRCPC; and Carmen Kosicek, MSN, PMHNP-BC, discuss provider and patient communication about the time to onset of action of major depressive disorder (MDD) treatments and when the patient can expect to see a difference.

EP. 4: New Treatment Options in MDD

October 5th 2023

Roger S. McIntyre, MD, FRCPC; and Carmen Kosicek, MSN, PMHNP-BC; review the mechanism of action of newer therapies in MDD treatment.

EP. 5: GABAA Receptor Modulators for Treatment of MDD

October 12th 2023

Experts in psychiatry comment on the use of GABAA receptor modulators in the treatment of major depressive disorder (MDD), highlighting zuranolone.

EP. 6: Dosing Considerations of Zuranolone in MDD

October 12th 2023

Carmen Kosicek, MSN, PMHNP-BC, shares considerations on the perception of mental health treatment among diverse cultures and ages within the United States.

EP. 7: GABAergic Modulating Treatment Considerations in MDD

October 19th 2023

Roger S. McIntyre, MD, FRCPC, comments on the paradigm shift of the frequency of dosing in the treatment of MDD, highlighting GABAergic modulating treatments, as well as the use of therapy to improve mental health.

EP. 8: Potential Adverse Effects of Zuranolone in MDD

October 19th 2023

Experts in psychiatry review adverse effects of zuranolone, a γ-aminobutyric acid (GABA) receptor modulator, in the treatment of MDD.

EP. 9: Practical Considerations of Zuranolone Use in Treatment of MDD

October 26th 2023

Carmen Kosicek, MSN, PMHNP-BC, shares tips with patients about the use of zuranolone to treat MDD.

EP. 10: Closing Thoughts on the Treatment of MDD

October 26th 2023

Roger S. McIntyre, MD, FRCPC, and Carmen Kosicek, MSN, PMHNP-BC, discuss the future of MDD treatment and share closing thoughts.